Chidamide and Lisaftoclax with Chemotherapy for Aggressive Lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (chidamide, lisaftoclax, and standard chemotherapy) to treat a serious type of blood cancer called double-hit or triple-hit diffuse large B-cell lymphoma. The goal is to see if adding these newer drugs to standard treatment improves how well the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with diffuse large B-cell lymphoma confirmed by biopsy, with a specific genetic pattern (double-hit or triple-hit)
- Age 65 or older
- Overall health status allowing you to perform light daily activities (ECOG score 0–2)
- No history of other cancers (except skin or cervical cancer in situ)
- Life expectancy of at least 6 months
- Certain blood counts and liver/kidney function within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
This trial tests a combination of three drugs (lisaftoclax, chidamide, and rituximab) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatments. The goal is to see if this combination can help patients whose disease hasn't responded to standard chemotherapy and who aren't candidates for stem cell transplant.
This trial tests a new drug called Lisatoclax added to standard chemotherapy (R-CHOP or Pola-R-CHP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better and is safe.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new DHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.